anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Preoperative coagulation tests have not been shown to be effective in predicting bleeding complications. The Pediatric Bleeding Questionnaire (PBQ) is a proven and sensitive tool for diagnosing children with a predisposition to bleeding. The aim of this study was to evaluate the usefulness of PBQ as a preoperative screening tool for the prediction of bleeding after minor surgical interventions.
METHODS: Preoperative coagulation tests and PBQ were performed in all patients who underwent minor surgery. The postoperative bleeding status was evaluated and then compared with the coagulation tests and PBQ of the patients.
RESULTS: Evaluation was made of a total of 706 patients, comprising 91.2% males and 8.8% females, with a mean age of 4.8 years (median: 4 y, QR: 1 to 7 y). Prolongation in coagulation tests was observed in 131 (18.5%) patients. Repeated tests in 116 patients were within the normal range, and 5 patients received treatment. Postoperative bleeding occurred in 4 (0.5%) patients. The relationship between coagulation tests and postoperative bleeding was not significant. PBQ was found to be ≥2 in 14 patients, but none of these patients had postoperative bleeding. No significant relationship was found between postoperative bleeding status and PBQ ( p :0.77). The sensitivity, specificity, positive predictive, and negative predictive values of PBQ were 0%, 98%, 0%, and 97.4%, respectively.
CONCLUSIONS: The results of this study demonstrated that neither coagulation tests nor PBQ will be sufficient to predict bleeding after minor surgery, that prolongation in coagulation tests does not always indicate a bleeding tendency, and that bleeding history should also be recorded in detail.
1,149,557. Aminoalkyldihydroethanoanthracenes. CIBA Ltd. 12 Dec., 1966 [10 Dec., 1965], No. 55554/66. Heading C2C. Novel ethano-anthracenes of the formula where A represents a dimethylamino or diethylamino group and the ethano-anthracene is substituted in the 2- or 3-position by chlorine, and salts thereof, are obtained from a compound of the formula which is substituted in the 2- or 3-position by a Cl atom, and in which X represents a dimethylaminomethyl or diethylaminomethyl group in which at least one of the methylene groups vicinal to the nitrogen atom is replaced by a carbonyl group, by selective reduction of the carbonyl group to a methylene group, for example by means of LiAlH 4  or an analogous amide reducing agent. Alternatively a compound of the second formula above in which X represents a dimethylaminomethyl or diethylaminomethyl group which contains either a hydroxy group in the α-position to the nitrogen atom or a C-N double bond is reduced to convert X into the dimethylaminomethyl or diethylaminomethyl group, for example by means of a metal hydride, such as an alkali metal borohydride, or of catalytically activated hydrogen with catalysts such as platinum oxide and Raney nickel. A further modification comprises reacting the corresponding ethanoanthracene in which the 9-position contains an aminomethyl, methylaminomethyl or ethylaminomethyl group with formaldehyde or acetaldehyde in the presence of a reducing agent. The free bases may be converted to salts, especially to physiologically tolerable salts. A list of suitable acids is given. Intermediates are prepared as follows: A mixture of 2-chloroanthracene, N-methylformamide, POCl 3  and dichlorobenzene is heated to form 2-chloro-anthracene-(9)-aldehyde which is saturated with ethylene and heated in an autoclave, then heated with methylamine, hydrogenated and acidified to form 2 - chloro- 9 - methylaminomethyl - 9: 10 - dihydro - 9: 10- ethano - (1:2) anthracene - hydrochloride. Similarly, using ethylamine in place of methylamine, there is obtained 2-chloro-9-ethylaminomethyl - 9,10 - dihydro - 9,10 - ethano - (1,2)- anthracene which is reacted with acetic anhydride to form the corresponding N-acetyl compound. Pharmaceutical and veterinary compositions, useful as psychotropic, sedative medicaments, comprise a compound of the first formula above in admixture or conjunction with a suitable diluent. The compositions may be in forms suitable for oral or parenteral administration or may be in the form of animal fodder or additives to animal fodder.
The CCR/L5 axis is known for its role in immune regulation in a variety of settings and has been shown to have dichotomous functions in cancer, influencing both tumor progression and immune responses. Battaglin et al investigated its role using genomic and transcriptomic data from several datasets of patients with advanced colorectal cancer (CRC), including patients treated on CALGB/SWOG 80405, a trial of chemotherapy plus cetuximab versus bevacizumab, as well as a larger population of patients whose CRCs underwent commercially available Caris NGS and CODEai assays. These authors showed that CCR/L5 expression was both prognostic and predictive. They reported that low expression of the CCR/L5 axis was correlated with improved survival broadly, with particular benefit in patients treated with chemotherapy plus cetuximab. They demonstrated that high expression of CCR/L5 was associated with infiltration by negatively prognostic Tregs, M1 and M2 macrophages, myeloid-derived suppressor cells, and cancer-associated fibroblasts. They also showed that increased expression was correlated a wide variety of immune suppressive proteins, including PD-1, PD-L1, PD-L2, CTLA4, CD80, CD86, TIM3, IDO1, LAG3, and IFN-γ. This suggests mechanisms by which CRC resists anti-cancer immune responses. This study enhances our understanding of the role of the CCR/L5 axis in advanced CRC.
Lymphatic vessels are actively involved in the recovery process of inflamed tissues. However, the changes in intramuscular lymphatic vessels during inflammation caused by skeletal muscle injury remain unclear. Therefore, the purpose of this study was to clarify the changes in lymphatic vessels after skeletal muscle injury. The left tibialis anterior muscles of male mice were subjected to lengthening contractions (LC) for inducing skeletal muscle injury, and samples were collected on Days 2, 4, and 7 for examining changes in both the skeletal muscles and intramuscular lymphatic vessels. With hematoxylin-eosin staining, the inflammatory response was observed in myofibers on Days 2 and 4 after LC, whereas regeneration of myofibers was found on Day 7 after LC. The number and area of intramuscular lymphatic vessels analyzed by immunohistochemical staining with an antibody against lymphatic vessel endothelial hyaluronan receptor 1 were significantly increased only on Day 4 after LC. Based on the abovementioned results, intramuscular lymphatic vessels undergo morphological changes such as increase under the state of muscle inflammation. This study demonstrated that the morphology of intramuscular lymphatic vessels undergoes significant changes during the initial recovery phase following skeletal muscle injury.
OBJECTIVES: I. Determine the maximum target-inhibiting dose of SU5416 in patients with advanced solid tumors. II. Determine the relationship between dose or plasma levels and the clinical safety profile and antitumor effects of this treatment regimen in terms of objective response, stabilization of disease, or progression-free survival in this patient population. III. Evaluate the relationship between dose or plasma levels of SU5416 concentrations and the ability of this treatment regimen to reduce microvessel density and induce apoptosis of endothelial and tumor cells in this patient population. IV. Determine prognostic and surrogate serologic markers in these patients treated with this regimen. V. Determine if pre and posttreatment plasma and serum levels of angiogenic growth factors, basic fibroblast growth factor, and vascular endothelial cell growth factor are prognostic in predicting patient response to this regimen. VI. Determine if elevated plasma levels of endothelial cell specific proteins reflective of SU5416-induced endothelial damage and/or apoptosis are useful surrogate markers in assessing response to this treatment regimen in these patients.

OUTLINE: This is a dose-deescalation study. Patients receive SU5416 IV over 1 hour twice weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 6-12 patients receive deescalating doses of SU5416 until the maximum target-inhibiting dose (MTID) is determined. The MTID is defined as the dose at which patients experience no greater than grade 1 toxicity. Patients are followed every 3 months.

PROJECTED ACCRUAL: Approximately 20-30 patients will be accrued for this study.
A tincture containing 149mg sunflower lecithin (8.0%), 56mg peppermint oil (3.0%), 1661mg hempseed oil (89.0%) will be administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
Participants will receive 20 minutes of contingent recorded mother' voice also at 45 dBA, during two 20-minute sessions, with a maximum of 2 sessions per day. The smallTalk Active system integrates a wireless, lightweight and sealed sensor unit that securely fits into a Philips NICU Soothie pacifier. The speaker device is factory set to communicate constantly with the sensor unit, and to only deliver a predetermined 10 seconds of recorded parent's voice upon detection of a suck that meets a pressure threshold, which is automatically set by the speaker device.
PROBLEM TO BE SOLVED: To obtain an adsorbent for alkylphenol-based compounds having adsorbing actions on the alkylphenol-based compounds and promoting the extracorporeal discharge of the alkylphenol-based compounds by composing the adsorbent of dietary fibers. SOLUTION: This adsorbent for alkylphenol-based compounds is obtained by composing the adsorbent of dietary fibers. The dietary fibers refer to sparingly digestible polysaccharides or lignin usually contained in foods and unhydrolyzed by human digestive enzymes at the time of ingestion. The dietary fibers used in the adsorbent for the alkylphenol-based compounds are preferably insoluble in water. Cacao mass dietary fibers, cacao husk dietary fibers, rice bran dietary fibers, wheat bran dietary fibers, amaranth dietary fibers, soybean dietary fibers, spinach dietary fibers, or the like, are preferably used as the water-insoluble dietary fibers. Bisphenol A, p-nonylphenol, p-t-octylphenol, or the like, are cited as the alkylphenol-based compounds.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to liposome vectors of active substances consisting of powdery composition. The compositions comprises mainly unilamellar liposomes with external lipid phase formed by lipids of 4-th class (phospholipids) associated in necessary with substances of 2-d class, substances of 3-d class and/or substances of 5-th class (bile acid salts, derivatives of fusidic acid) and with internal aqueous core. The core is formed by mixture M of at least two different gelatinizing non-polymerizing substances G1 and G2 with temperature of phase transition "gel-sol" 37 C or above. The substance G1 is gelatinizing substance taken among gelatins and carragheenans with melting point 45 C or lower and G2 is taken among carragheenans with properties distinguishing from carragheenans for G1 and celluloses. Melting point of gelatinizing substance G2 is 45 C or above and liposomes have diameter from 20 nm to 1 mcm but preferably from 20 nm to 500 nm. The indicated composition shows particles with mean diameter from 10 mcm to 1000 mcm consisting of one or some indicated liposomes surrounded by envelope taken among group comprising dehydrated thermoreversible aqueous gel that is similar with gel of internal core, dextrins or their mixture to provide an average 10 16 -10 18  liposomes/g of powder and at least one active substance added into either gelatinizing internal core or in external lipid phase. Invention ensures to prepare powder- like compositions eliciting required properties, in part, improved bioavailability in oral route of administration. EFFECT: improved and valuable properties of vectors. 19 cl, 9 dwg
This is a pilot 2A trial of an innovative behavioral economics theory-based antidote for physician inertia in the medical treatment of hypertension (HTN). In the current reactive physician-centered model, blood pressure (BP) is measured and medical decisions are made in the physician office; when deciding whether or not to prescribe new medication for a high office BP reading, the physician's default behavior is inaction. The investigators propose default medication intensification as a new patient-centered/pharmacist-assisted proactive treatment model to eliminate physician inertia. For enrolled patients with office BP\>155/95, the physician will prescribe a one-month protocol that automatically escalates drug dose and drug number each week. The pharmacist will fill the prescription in a blister pack to simplify adherence. The patient will measure daily home BP with an iPhone cuff that transmits the data electronically to the pharmacist, who will halt the protocol if goal home BP\<135/85 is achieved ahead of schedule. the investigators will pilot test the feasibility and safety of self-monitoring plus the new automatic intensification protocol packaged in blisters. Default medication intensification could revolutionize HTN treatment and reduce healthcare costs.
Psycho-education groups (12-18 members/group; 10 two-hour sessions, weekly/biweekly), 4-month duration similar to the PLSMI, will be led by one trained advanced practice psychiatric nurse in each center experienced in psychiatric rehabilitation, and are guided by a validated group-intervention protocol based on the research team's and McFarlane et al.'s psycho-education programs for psychosis.
The probiotic tablets contain Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2 at a dose of 1 \* 109 CFU/tablet. The participants will take two tablets a day for four weeks.
Triple negative breast cancer (TNBC) is insensitive to conventional targeted therapy and endocrine therapy, and is characterized by high invasiveness and high recurrence rate. This study aimed to explore the role and mechanism of RHOXF2 and HOXC13 on the malignant progression of TNBC. RT-qPCR and western blot were used to detect RHOXF2 and HOXC13 expression in TNBC cells. The proliferation, colony formation, invasion, migration, apoptosis and cell cycle of TNBC cells after transfection were analyzed by CCK-8 assay, colony formation assay, transwell assay, wound healing assay and flow cytometry analysis. Co-Immunoprecipitation and GST pull-down assays were used to analyze the combination between RHOXF2 and HOXC13. ChIP-PCR and luciferase reporter gene assay were used to examine the regulation of H3K27ac on RHOXF2. Besides, the expression of Ki67 and cleaved Caspase3 in tumor tissues of nude mice was determined by immunofluorescence. Results revealed that RHOXF2 and HOXC13 expression was increased in TNBC cells. RHOXF2 knockdown suppressed the proliferation, invasion and migration, as well as induced G0/G1 cell cycle arrest and apoptosis of TNBC cells. Besides, RHOXF2 could bind to HOXC13 and RHOXF2 knockdown suppressed HOXC13 expression in TNBC cells. Furthermore, HOXC13 overexpression reversed the impacts of RHOXF2 downregulation on the proliferation, invasion, migration, G0/G1 cell cycle arrest and apoptosis of TNBC cells. In addition, RHOXF2 silencing limited the tumor volume in nude mice, which was reversed by HOXC13 overexpression. Moreover, RHOXF2 knockdown interfered with Wnt2/β-catenin pathway in vitro and in vivo by binding to HOXC13. Importantly, H3K27ac acetylation could activate the expression of RHOXF2 promoter region. In conclusion, RHOXF2 activated by H3K27ac functioned as a tumor promoter in TNBC via mediating Wnt2/β-catenin pathway by binding to HOXC13, which provided promising insight into exploration on TNBC therapy.
Cartilage restoration, in general, is a relatively new option for the treatment of articular cartilage lesions primarily of the knee. In the initial autologous cultured chondrocyte transplantation (ACT or, by others implantation, thus ACI) reported by Peterson et. al., the results of femoral lesions were favorable, while 5 of 7 patellofemoral treatments were poor. In the United States, the expedited FDA approval based on these results excluded the patella. As a result, in the United States, it has been difficult to further evaluate use of ACI at the patellofemoral joint in light of the exclusion of "off label" uses by many governmental and private insurance programs. Nevertheless, a growing body of knowledge is accumulating outside the United States that the use of ACI at the patella is a viable option and soon similar findings will be published in the US by Minas et. al. (accepted for publication)
Postoperative delirium (POD) is a transient and usually fully reversible altered state of consciousness that develops acutely or subacutely after surgery, characterized by widespread, daily fluctuations in brain metabolism and function. It can be seen as hyperactive (mania), hypoactive (depressive) and mixed type. It has been shown to be associated with increased morbidity, mortality, health expenditures and prolonged hospitalization in the postoperative period. In studies, the frequency of POD was found to be 17-51% in orthopedic surgery, 11-46% in cardiac surgery and 13-50% in non-cardiac surgery. There are many studies in the literature on advanced age, comorbidities (e. g; diabetes mellitus, stroke, coronary artery disease, arrhythmias), dementia, use of glasses-hearing aids, medications (anticholinergic, opioid, benzodiazepine etc. ), duration of anesthesia, type of surgery, electrolyte disturbances, perioperative bleeding, hypotension, pain and intensive care unite stay as risk factors associated with delirium. This condition, which has a multifactorial etiology, is often unrecognized, unpreventable, untreatable and leads to increased morbidity and mortality. Therefore, it is important to recognize delirium that develops in the postoperative period and to perform the necessary interventions.

There are many tests used in the diagnosis of POD. Delirium tests; it evaluates the patient under many sub-headings such as orientation, memory, attention, visual and spatial ability. The gold standard method is DSM-V (North American Diagnostic and Statistical Manual-V of Mental Disorders-V) to assess delirium status. There are also some other tests like DRS-R-98 (The Delirium Rating Scale--Revised-98) and 3D-CAM (3-minute diagnostic assessment for CAM-Confusion Assessment Method-defined delirium). In addition to patient assessment, these tests are useful for the clinician in the diagnosis of delirium. The aim of the study is to compare the DRS-R-98 and 3D-CAM tests used in the assessment of POD, and to evaluate their feasibility and the power detecting delirium.

After obtaining ethics committee approval, all patients who undergo orthopedic, urological, general surgery, thoracic and vascular surgery operations in the Istanbul Faculty of Medicine, above 65 years old, with an operation duration longer than 60 minutes will include in this study. Patients who are re-operated, require re-intubation or withdraw their consent will be excluded from the study. This study is planned as an observational, prospective study. Demographic information such as age, gender, height, weight, comorbidities, duration of operation and anesthesia, postoperative pain level, anesthesia and analgesia management, intensive care and hospitalization periods will be recorded from their files. On postoperative day 1, delirium development will be evaluated with DSM-5 diagnostic criteria. All patients will also be evaluated by another physician with both DRS-R-98 and 3D-CAM tests. The same tests will be repeated on postoperative day 2.
PURPOSE:A styptic useful as a remedy for pulmonary hemorrhage, cerebral hemorrhage, purpura, etc., having higher hemostatic action than ethamsylate and tranexamic acid, containing pectolinarin extracted from Cirsium japonicum DC. for Chinese herbal remedy as an active ingredient. CONSTITUTION:A styptic containing pectolinarin shown by the formula as an active ingredient. The compound shown by the formula is obtained by extracting Cirsium japonicum DC. with hot water, treating the prepared extracted essence by counter current partition, removing water-soluble substances, then fractionating and purifying a prepared fraction by column chromatography and purifying an active fraction by recrystallization. The compound shown by formula is administered orally or parenterally. A dose is preferably 3-6mg/time by oral administration.
The present disclosure relates to treatment of transfusion-dependent in myelodysplastic syndrome (MDS). The present disclosure relates to methods of treating transfusion dependency in a subject in need thereof using novel biomarkers. The disclosure also relates to methods of identifying a subject with MDS suitable for treatment with a splice modulator and/or predicting or monitoring the efficacy of treatment in a subject with MDS. In some embodiments, the methods disclosed herein comprise determining at least the ratio of aberrant ligation to canonical ligation TMEM14C transcripts (TMEM 14C AJ/CJ ratio) in the patient. In some embodiments, the methods disclosed herein comprise administering a therapeutically effective amount of a splicing modulator (e.g., compound 1) based on the TMEM14C AJ/CJ ratio of the patient. Therapeutic uses and compositions are also disclosed.
In a thorough QT study, Citalopram was found to be associated with a dose-dependent increase in the QTc interval (see WARNINGS - QT-Prolongation and Torsade de Pointes). 

Electrocardiograms from citalopram (N=802) and placebo (N=241) groups were compared with respect to outliers defined as subjects with QTc changes over 60 msec from baseline or absolute values over 500 msec post-dose, and subjects with heart rate increases to over 100 bpm or decreases to less than 50 bpm with a 25% change from baseline (tachycardic or bradycardic outliers, respectively). In the citalopram group 1.9% of the patients had a change from baseline in QTcF >60 msec compared to 1.2% of the patients in the placebo group. None of the patients in the placebo group had a post-dose QTcF >500 msec compared to 0.5% of the patients in the citalopram group. The incidence of tachycardic outliers was 0.5% in the citalopram group and 0.4% in the placebo group. The incidence of bradycardic outliers was 0.9% in the citalopram group and 0.4% in the placebo group.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to pharmaceutical compositions containing irbesartan, filling agent, binding agent, disintegrator, antiadhesive agent, lubricating agent and surface-active substance. Invention proposes also a tableted form of composition. Compositions have the more high content of active substance and can be tableted easily. EFFECT: improved quality and properties of compositions. 12 cl, 7 tbl, 4 ex
<P>PROBLEM TO BE SOLVED: To provide a new collagenase activity inhibitor.  <P>SOLUTION: A potato extract has been found to have a collagenase activity-inhibiting action. This collagenase activity inhibitor is characterized by containing the potato extract. The potato extract is preferably a fraction having a mol.wt. of ≥10,000. The potato extract can be used as it is, or in the form of foods, drinks or cosmetics mixed with various additives, as the collagenase activity inhibitor.  <P>COPYRIGHT: (C)2010,JPO&INPIT